Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Jul;3(3):260-7.
doi: 10.1007/BF00915350.

Construction of an antigenic map for human B-cell precursors

Construction of an antigenic map for human B-cell precursors

G B Melink et al. J Clin Immunol. 1983 Jul.

Abstract

The purpose of this study was to evaluate the binding of a panel of monoclonal antibodies to human pre-B cells present in fetal, pediatric, and adult bone marrow. The antibodies included BA-1, BA-2, BA-3 (anti-CALLA), anti-B1, L243 (anti-HLA-DR), and T101. Binding of the monoclonal antibodies to pre-B cells was evaluated at the single-cell level by double fluorochrome analysis. Percentages of BA-1+ and anti-B1+ pre-B cells were independent of age group. BA-1 bound to approximately 80% of fetal, pediatric, and adult bone marrow pre-B cells, whereas anti-B1 bound to approximately 50%. BA-2 bound to 55% of fetal pre-B cells, but this percentage decreased to 32% in pediatric and 16% in adult bone marrow. CALLA was expressed on less than 10% of fetal, pediatric, and adult bone marrow pre-B cells, and HLA-DR was expressed on greater than 95% of fetal, pediatric, and adult pre-B cells. Although T101 (an anti-T-cell monoclonal antibody) did not bind to pre-B cells, it did bind to approximately 25% of the sIgM+ cells in fetal bone marrow. These results suggest a predominant phenotype of L243 (anti-HLA-DR)+, BA-1+, BA-3 (anti-CALLA)-, T101- for the human pre-B cell while phenotypic heterogeneity exists for anti-B1 and BA-2.

PubMed Disclaimer

References

    1. J Immunol. 1982 Aug;129(2):526-31 - PubMed
    1. J Immunol. 1980 Jul;125(1):293-9 - PubMed
    1. J Clin Invest. 1982 Aug;70(2):433-42 - PubMed
    1. J Immunol. 1980 Oct;125(4):1678-85 - PubMed
    1. J Immunol. 1978 Apr;120(4):1169-75 - PubMed

Publication types

LinkOut - more resources